352 related articles for article (PubMed ID: 16882098)
21. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
[TBL] [Abstract][Full Text] [Related]
22. [Antihypertensive therapy: campaign of the giants].
Füessl HS
MMW Fortschr Med; 2005 Dec; 147(51-52):28. PubMed ID: 16402700
[No Abstract] [Full Text] [Related]
23. [Risk oriented therapy of hypertension. Lowering blood pressure and risk].
MMW Fortschr Med; 2007 Nov; 149(46):53. PubMed ID: 18069196
[No Abstract] [Full Text] [Related]
24. Coronary heart disease benefits from blood pressure and lipid-lowering.
Sever PS; Poulter NR; Mastorantonakis S; Chang CL; Dahlof B; Wedel H;
Int J Cardiol; 2009 Jun; 135(2):218-22. PubMed ID: 19232755
[TBL] [Abstract][Full Text] [Related]
25. Progress in cardiovascular diseases: cognitive function in essential hypertension.
Birkenhäger WH; Staessen JA
Prog Cardiovasc Dis; 2006; 49(1):1-10. PubMed ID: 16867845
[TBL] [Abstract][Full Text] [Related]
26. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.
Dolan E; Stanton AV; Thom S; Caulfield M; Atkins N; McInnes G; Collier D; Dicker P; O'Brien E;
J Hypertens; 2009 Apr; 27(4):876-85. PubMed ID: 19516185
[TBL] [Abstract][Full Text] [Related]
27. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
[TBL] [Abstract][Full Text] [Related]
28. [HOSP study].
Kawano Y
Nihon Rinsho; 2006 Aug; 64 Suppl 6():465-9. PubMed ID: 16983778
[No Abstract] [Full Text] [Related]
29. Single-pill combination of amlodipine and valsartan in the management of hypertension.
Flack JM; Hilkert R
Expert Opin Pharmacother; 2009 Aug; 10(12):1979-94. PubMed ID: 19606937
[TBL] [Abstract][Full Text] [Related]
30. What your blood pressure isn't revealing.
Johns Hopkins Med Lett Health After 50; 2010 Nov; 22(9):4-5. PubMed ID: 21066836
[No Abstract] [Full Text] [Related]
31. Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials.
Wang JG; Yan P; Jeffers BW
J Am Soc Hypertens; 2014 May; 8(5):340-9. PubMed ID: 24685006
[TBL] [Abstract][Full Text] [Related]
32. A study of pulmonary profile of hypertensive patients--comparison of atenolol vs amlodipine.
Chaswal M; Singh S; Tandon OP; Shankar N
Indian J Physiol Pharmacol; 1998 Oct; 42(4):538-42. PubMed ID: 10874357
[TBL] [Abstract][Full Text] [Related]
33. [An overview of hypertension studies with calcium antagonists].
Kjeldsen SE; Midtbø K; Os I; Westheim A
Tidsskr Nor Laegeforen; 1999 May; 119(13):1878-82. PubMed ID: 10382332
[TBL] [Abstract][Full Text] [Related]
34. Antihypertensive treatment in the very elderly shows significant mortality benefit.
Cardiovasc J Afr; 2008; 19(3):169-71. PubMed ID: 18568185
[No Abstract] [Full Text] [Related]
35. [Treating essential hypertension. Are beta blockers still first choice?].
Rahn KH
MMW Fortschr Med; 2007 May; 149(18):43-5. PubMed ID: 17672414
[No Abstract] [Full Text] [Related]
36. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
[TBL] [Abstract][Full Text] [Related]
37. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
38. 'Beyond blood pressure' means multiple risk factor intervention, not pleiotropic antihypertensive drugs.
Staessen JA; Thijs L; Li Y; Kuznetsova T; Richart T; Wang J; Birkenhäger WH
Curr Opin Cardiol; 2007 Jul; 22(4):335-43. PubMed ID: 17556887
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
[TBL] [Abstract][Full Text] [Related]
40. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
